{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-060904","form_type":"8-K","ticker":"BRVE","cik":"0002131524","company_name":"Braveheart Bio, Inc.","filed_at":"2026-09-08T20:06:55+00:00","discovered_at":"2026-09-08T20:08:03.415823+00:00","generated_at":"2026-09-08T20:08:10.215688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Braveheart Bio Q2 2026 net loss $18.6M; cash $527.3M after IPO; Phase 3 trials advancing","bullets":["Cash $122.8M at 6/30/26; $527.3M pro forma after Aug IPO net ~$404.5M; runway into 2029.","Net loss $15.0M; attributed to common stockholders $18.6M ($2.51/sh) vs $0.4M ($0.14/sh) in Q2 2025.","LIONHEART-HCM Phase 3 for oHCM initiated; first patient dosing expected 2026, interim results 2H 2027.","NOBLEHEART-HCM Phase 3 in nHCM expected to start 1H 2027 after Q2 Phase 2 data presented at HFA-ESC 2026.","R&D expense $11.1M (vs $0.0M), G&A $4.8M (vs <$0.1M) on advancement and public-company prep."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-060904","json":"https://secwatch.observer/filing/0001628280-26-060904.json","markdown":"https://secwatch.observer/filing/0001628280-26-060904.md","text":"https://secwatch.observer/filing/0001628280-26-060904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/0001628280-26-060904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/bhb-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T20:08:10.215688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}